Starling Oncology (STLNW) Other Non-Current Liabilities (2020 - 2026)

Starling Oncology (STLNW) has reported Other Non-Current Liabilities for 7 consecutive years, with $10.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities rose 41.1% year-over-year to $10.8 million; the trailing twelve-month figure through Jun 2026 stood at $10.8 million (up 41.1% YoY), and the FY2025 full-year result was $12.6 million, up 3170.39% from the prior year.
• Other Non-Current Liabilities improved to $10.8 million in Q2 2026 per STLNW's latest filing, from $7.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $20.6 million in Q1 2022 and bottomed at $385000.0 in Q4 2024.
• Historically, Other Non-Current Liabilities has averaged $6.3 million across 5 years, with a median of $3.8 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities sank 96.28% in 2023, then surged 3170.39% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $4.0 million in 2022, then retreated by 22.17% to $3.1 million in 2023, then sank by 87.51% to $385000.0 in 2024, then soared by 3170.39% to $12.6 million in 2025, then fell by 13.92% to $10.8 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $10.8 million, $7.6 million, and $12.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.